Screener
LENZ Therapeutics, Inc. LENZ Q3 2026 earnings
Reported October 29, 2026 · Before market open
Revenue$3.4MMiss by $816.6K
EPS-$0.99Miss by $0.10
Revenue estimate$4.2M
EPS estimate-$0.89
“Our strong third-quarter results demonstrate continued progress in the commercialization of VIZZ, with product sales growth of 50%, increasing patient adoption and encouraging refill rates. We view these as promising indicators of our positive trajectory in this emerging market. We are focusing our commercial organization and investment on initiatives we believe will most effectively increase consumer awareness, access and adoption, while improving capital efficiency and supporting VIZZ's continued growth. I am encouraged by the growing third-quarter consumer demand that is continuing into the fourth quarter, and excited about the opportunities ahead for LENZ.”
Next report
Date not yet announcedVersus estimates
Revenue
Diluted EPS
FAQ
- When did LENZ Therapeutics, Inc. report Q3 2026 earnings?
- LENZ Therapeutics, Inc. (LENZ) reported Q3 2026 earnings on October 29, 2026 before market open.
- What were LENZ Therapeutics, Inc.'s Q3 2026 revenue and EPS?
- LENZ Therapeutics, Inc. reported revenue of $3.4M and eps of $-0.99 for Q3 2026.
- Did LENZ Therapeutics, Inc. beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $4.2M by $816.6K. EPS missed the consensus estimate of $-0.89 by $0.10.
- How did LENZ Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 72.9% from $12.5M a year earlier and eps declined 67.8% from $-0.59.
- Where can I find LENZ Therapeutics, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001815776-26-000056) directly on SEC EDGAR. The filing index links above go to sec.gov.
